Moderna’s COVID-19 vaccine produces immune response in early trial
Moderna’s highly-anticipated COVID-19 vaccine candidate has shown promise in a key early trial, producing antibodies in all partcipants tested.
The interim analysis of the phase 1 study of the candidate, mRNA-1273, evaluated a two-dose vaccination schedule of the shot given 28 days apart across three dosages – 25, 100, 250 µg – in 45 healthy adults aged 18-55 years. The initial results from participants who received both doses showed mRNA-1273 produced rapid and strong immune responses against SARS-CoV-2, the virus which causes COVID-19.
Despite producing a promising immune response in all patients, the vaccine also caused side effects, including mild to moderate fatigue, chills, headache and muscle pain.
In addition to those milder side effects, 40% of participants in the middle-dose group experienced a fever after the second vaccinations, with three of the 14 patients in the high-dose group experiencing severe side effects.
Read more: http://www.pmlive.com/pharma_news/modernas_covid-19_vaccine_produces_immune_response_in_early_trial_1344907
The interim analysis of the phase 1 study of the candidate, mRNA-1273, evaluated a two-dose vaccination schedule of the shot given 28 days apart across three dosages – 25, 100, 250 µg – in 45 healthy adults aged 18-55 years. The initial results from participants who received both doses showed mRNA-1273 produced rapid and strong immune responses against SARS-CoV-2, the virus which causes COVID-19.
Despite producing a promising immune response in all patients, the vaccine also caused side effects, including mild to moderate fatigue, chills, headache and muscle pain.
In addition to those milder side effects, 40% of participants in the middle-dose group experienced a fever after the second vaccinations, with three of the 14 patients in the high-dose group experiencing severe side effects.
Read more: http://www.pmlive.com/pharma_news/modernas_covid-19_vaccine_produces_immune_response_in_early_trial_1344907
